About this Course
UConn has developed web-based continuing pharmacy education activities to enhance the practice of pharmacists and assist pharmacists in making sound clinical decisions to affect the outcome of anticoagulation therapy for the patients they serve. There are a total of 17.25 hours of CPE credit available. Successful completion of these 17.25 hours (13 activities) or equivalent training will prepare the pharmacist for the Anticoagulation Traineeship, which described below in the Additional Information Box.
The activities below are available separately for $17/hr or as a bundle price of $199 for all 13 activities (17.25 hours). These are the pre-requisites for the anticoagulation traineeship. Any pharmacist who wishes to increase their knowledge of anticoagulation may take any of the programs below.
When you are ready to submit quiz answers, go to the Blue "Take Test/Evaluation" Button.
Target Audience
Pharmacists who are interested in making sound clinical decisions to affect the outcome of anticoagulation therapy for the patients they serve.
This activity is NOT accredited for technicians.
Pharmacist Learning Objectives
At the completion of this activity, the participant will be able to:
|
|
|
|
Release Date
Released: 07/15/2025
Expires: 07/15/2028
Course Fee
$21.25
ACPE UAN
ACPE #0009-0000-25-040-H01-P
Session Code
25AC40-VXT88
Accreditation Hours
1.25 hours of CE
Bundle Options
If desired, “bundle” pricing can be obtained by registering for the activities in groups. It consists of thirteen anticoagulation activities in our online selection.
You may register for individual topics at $17/CE Credit Hour, or for the Entire Anticoagulation Pre-requisite Series.
Pharmacist General Registration for 13 Anticoagulation Pre-requisite activities-(17.25 hours of CE) $199.00
In order to attend the 2-day Anticoagulation Traineeship, you must complete all of the Pre-requisite Series or the equivalent.
Additional Information
Anticoagulation Traineeship at the University of Connecticut Health Center, Farmington, CT
The University of Connecticut School of Pharmacy and The UConn Health Center Outpatient Anticoagulation Clinic have developed 2-day practice-based ACPE certificate continuing education activity for registered pharmacists and nurses who are interested in the clinical management of patients on anticoagulant therapy and/or who are looking to expand their practice to involve patient management of outpatient anticoagulation therapy. This traineeship will provide you with both the clinical and administrative aspects of a pharmacist-managed outpatient anticoagulation clinic. The activity features ample time to individualize your learning experience. A “Certificate of Completion” will be awarded upon successful completion of the traineeship.
Accreditation Statement
The University of Connecticut, School of Pharmacy, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Statements of credit for the online activity ACPE #0009-0000-25-040-H01-P will be awarded when the post test and evaluation have been completed and passed with a 70% or better. Your CE credits will be uploaded to your CPE monitor profile within 2 weeks of completion of the program.
Grant Funding
There is no grant funding for this activity.
Requirements for Successful Completion
To receive CE Credit go to Blue Button labeled "take Test/Evaluation" at the top of the page.
Type in your NABP ID, DOB and the session code for the activity. You were sent the session code in your confirmation email.
Faculty
Michael White, Pharm.D., FCP, FCCP, FASHP
Distinguished Professor and Chair, Pharmacy Practice
UConn School of Pharmacy
Storrs, CT
Lyla White, PharmD Candidate 2026
UConn School of Pharmacy
Storrs, CT
Faculty Disclosure
In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.
Dr. White and Ms. White have no relationships with ineligible companies and therefore have nothing to disclose.
Disclaimer
The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.
Program Content
Program Handouts
Post Test
View Questions for Clinical Overview of Direct Oral Anticoagulants 2025
- If a patient is undergoing a percutaneous coronary intervention and already taking rivaroxaban daily for atrial fibrillation, what are the recommendations for dual antiplatelet therapy (DAPT) and oral anticoagulant therapy?
- There is no need for any antiplatelet therapy in this situation because rivaroxaban is sufficient to cover the risks with less bleeding risk
- DAPT therapy + rivaroxaban for one month and then the P2Y12 inhibitor + rivaroxaban for 5 months and then just rivaroxaban thereafter
- DAPT therapy + rivaroxaban is needed for 6 months and then rivaroxaban can be stopped with just DAPT therapy continued thereafter
- Which of the following agents would be unable to satisfactorily reverse the effects of the anticoagulant to which is was linked when used with in cases of life threatening bleeds such as intercranial hemorrhage?
- Idarucizumab reverses dabigatran
- Andexanet alfa reverses apixaban
- Vitamin K reverses edoxaban
- A 47-year-old patient with recurrent venous thromboembolism has a creatinine clearance of 99 mL/min. Which of the following oral anticoagulants should be avoided?
- All anticoagulants can be used
- Edoxaban should not be used
- Rivaroxaban should not be used
- A 67-year-old patient is currently taking itraconazole, a potent CYP3A4 inhibitor, for a toenail infection and has four months of therapy left. You want to start an oral anticoagulant that is not a substrate for CYP3A4 to avoid an interaction. Which of the following anticoagulants could you use?
- Rivaroxaban
- Apixaban
- Dabigatran
- A 49-year-old patient has chronic GERD and takes a proton pump inhibitor daily and occasional antacids for acute heartburn. Which of the following oral anticoagulants is most likely to exacerbate the acid reflux and to have mild drug interactions with the patient’s current medicatio?
- Rivaroxaban
- Apixaban
- Dabigitran
- A 77-year-old patient needs to be switched from warfarin to apixaban. When would you counsel the patient to start the apixaban?
- When the INR falls below 2
- At the time the next dose of warfarin was scheduled
- 48 hours after the last dose of warfarin
Additional Courses Available for Anticoagulation
Vitamin K Antagonist Pharmacology, Pharmacotherapy and Pharmacogenomics – 1 hour
Anticoagulation Management Pearls - 1.5 hour
Clinical Overview of Direct Oral Anticoagulants– 1.25 hour
Laboratory Monitoring of Anticoagulation – 2 hour
Heparin/Low Molecular Weight Heparin and Fondaparinux Pharmacology and Pharmacotherapy – 0.5 hours
Developing an Anticoagulation Clinic – 1.0 hour
Pharmacist Reimbursement for Anticoagulation Services – 0.5 hour
Risk Management in Anticoagulation – 1 hour
A Practical Approach to Perioperative Oral Anticoagulation Management – 2 hour
Management of Hypercoagulable States – 1.5 hour
Challenging Topics in Anticoagulation – 2 hour
Available Strategies to Reverse Anticoagulation Medications - 2 hour
Drug Interaction Cases with Anticoagulation Therapy – 1 hour